Voyager Therapeutics’ (VYGR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a $30.00 target price on the stock. HC Wainwright also issued estimates for Voyager Therapeutics’ FY2026 earnings at ($1.44) EPS, FY2027 earnings at ($1.35) EPS and FY2028 earnings at ($1.67) EPS.

Several other research firms have also issued reports on VYGR. Wedbush reduced their target price on Voyager Therapeutics from $10.00 to $8.00 and set a neutral rating for the company in a report on Tuesday, May 14th. Oppenheimer restated an outperform rating and set a $18.00 price objective on shares of Voyager Therapeutics in a report on Wednesday, May 15th. Finally, StockNews.com cut shares of Voyager Therapeutics from a buy rating to a hold rating in a research note on Monday, May 13th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $18.00.

Voyager Therapeutics Trading Down 4.4 %

Shares of Voyager Therapeutics stock opened at $8.30 on Wednesday. The company has a market capitalization of $451.44 million, a P/E ratio of -165.97 and a beta of 0.96. The stock has a fifty day simple moving average of $8.40 and a 200 day simple moving average of $8.39. Voyager Therapeutics has a 12-month low of $6.06 and a 12-month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Monday, May 13th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.24. Voyager Therapeutics had a negative net margin of 2.56% and a negative return on equity of 1.28%. The company had revenue of $19.52 million during the quarter, compared to the consensus estimate of $10.33 million. On average, analysts predict that Voyager Therapeutics will post -1.39 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VYGR. ADAR1 Capital Management LLC bought a new stake in Voyager Therapeutics during the fourth quarter valued at $1,569,000. Ritholtz Wealth Management boosted its position in shares of Voyager Therapeutics by 11.8% during the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock valued at $167,000 after acquiring an additional 2,089 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Voyager Therapeutics during the fourth quarter worth about $43,000. Assenagon Asset Management S.A. increased its position in shares of Voyager Therapeutics by 60.9% in the first quarter. Assenagon Asset Management S.A. now owns 28,896 shares of the company’s stock worth $269,000 after purchasing an additional 10,936 shares during the last quarter. Finally, AJOVista LLC purchased a new stake in Voyager Therapeutics in the fourth quarter valued at approximately $39,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.